Skip to main content
. 2022 Jun 7;12:911567. doi: 10.3389/fonc.2022.911567

Figure 7.

Figure 7

Analysis of survival and cumulative risk of relapse and early death for final low-risk patients without ETV6-RUNX1 positivity or hyperdiploidy ALL and didn’t meet the criteria for the second dose of daunorubicin.